Inspira technologies announces positive results from clinical study of hyla blood sensor, achieving 96% accuracy

Inspira's ai-powered continuous blood monitoring technology demonstrated a high degree of accuracy in a key parameter, targeting multiple multi-billion-dollar market segments; company plans to advance with ongoing clinical study following this success; fda submission planned for h2 2025 ra'anana, israel , march 4, 2025 /prnewswire/ -- inspira™ technologies oxy b.h.n. ltd. (nasdaq: iinn) ("inspira" or the "company"), a pioneer in innovative life-support and diagnostic technologies, today announced positive results from the clinical study of its ai-powered hyla™ blood sensor.
IINN Ratings Summary
IINN Quant Ranking